Praxis Precision Medicines公司宣布,其研发的药物Vormatrigine在临床试验中展现出良好的耐受性。数据显示,因不良事件而停止用药的患者比例被控制在10%以下,这一结果令人鼓舞。
Praxis Precision Medicines公司宣布,其研发的药物Vormatrigine在临床试验中展现出良好的耐受性。数据显示,因不良事件而停止用药的患者比例被控制在10%以下,这一结果令人鼓舞。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.